Bitcoin

Capital is flowing from risk‑off crypto assets into frontier biotech and health‑tech tokens as investors chase high‑alpha, low‑correlation opportunities. The study’s timing aligns with a broader macro‑fear environment (F&G 26) that is tightening liquidity for risk assets, making any biotech‑related hype a potential catalyst for sector rotation.

A study published in Nature reports that focal white matter lesions drive grey matter inflammation and synapse loss, and that transient grey matter microgliosis is required for remyelination.